as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,121.4
Change
-35.6 (-3.08%)
Open
₹1,162.3
Prev. Close
₹1,157.0
Day High
₹1,162.3
Day Low
₹1,117.2
Volume Analysis
Traded
304,843
Delivered
122,422
Delivery %
40.16%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (23.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (21.9%)
- •Strong 3-year revenue growth (36.2%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,195.16 | ₹1,178.73 | ₹1,150.06 | ₹1,133.63 | ₹1,104.96 | ₹1,088.53 | ₹1,059.86 |
| Fibonacci | ₹1,178.73 | ₹1,161.5 | ₹1,150.86 | ₹1,133.63 | ₹1,116.4 | ₹1,105.76 | ₹1,088.53 |
| Camarilla | ₹1,133.8 | ₹1,129.67 | ₹1,125.53 | ₹1,133.63 | ₹1,117.27 | ₹1,113.13 | ₹1,109.0 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+66.08%
1 Week
-0.35%
1 Month
+15.92%
3 Months
+30.61%
6 Months
+68.21%
1 Year
+43.52%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹275.24
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.78%
Net margin 13.04% × asset turnover 0.53x × equity multiplier 1.27x
Company Overview
Sector
Healthcare
Market Cap
₹10,805 Cr
P/E (TTM)
59.6
ROE
10.2%
Book Value
₹185.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 28 Sep 2026. Not investment advice.
TopFund Analysis
Yatharth Hosp & Tra C S L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (12/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%); promoter holding is falling. Strong 3-year EPS growth (21.9%).
TopFund Score — Fundamentals Quality
68/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 56.9% CAGR over last 5 years
- +Company's working capital requirements have reduced from 101 days to 80.1 days
- −Company has a low return on equity of 12.0% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Management to meet investors at Nuvama Emerging India CEO Forum on September 28 and sell-side meets on September 29, 2026.
We hereby submit the Newspaper Publication of the Notice for the 1st/2026-27 Extra-Ordinary General Meeting of the Company along with the e-voting information.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 155 | 171 | 167 | 178 | 212 | 218 | 219 | 232 | 258 | 279 | 320 | 342 | 393 |
| Expenses + | 113 | 126 | 120 | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 | 262 | 301 |
| Operating Profit | 41 | 46 | 46 | 47 | 54 | 55 | 55 | 57 | 64 | 65 | 74 | 80 | 92 |
| OPM % | 27.0% | 27.0% | 28.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 23.0% | 23.0% | 23.0% | 23.0% |
| Other Income + | 1 | 4 | 5 | 6 | 4 | 3 | 4 | 5 | 9 | 9 | 8 | 7 | 4 |
| Interest | 6 | 3 | 0 | 0 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 5 | 7 |
| Depreciation | 7 | 7 | 8 | 8 | 11 | 16 | 17 | 13 | 15 | 19 | 24 | 30 | 28 |
| Profit before tax | 29 | 40 | 44 | 44 | 43 | 40 | 40 | 49 | 59 | 55 | 57 | 52 | 61 |
| Tax % | 35.0% | 30.0% | 33.0% | 13.0% | 29.0% | 23.0% | 24.0% | 20.0% | 28.0% | 25.0% | 25.0% | 14.0% | 26.0% |
| Net Profit + | 19 | 28 | 29 | 38 | 30 | 31 | 30 | 39 | 42 | 41 | 43 | 45 | 45 |
| EPS in Rs | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 4 | 5 | 5 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 71 | 78 | 91 | 136 | 215 | 375 | 478 | 635 | 886 | 1,207 | 1,334 |
| Expenses + | 53 | 60 | 71 | 98 | 147 | 263 | 343 | 453 | 655 | 902 | 1,024 |
| Operating Profit | 18 | 18 | 20 | 38 | 68 | 112 | 135 | 182 | 230 | 305 | 310 |
| OPM % | 25.0% | 24.0% | 22.0% | 28.0% | 32.0% | 30.0% | 28.0% | 29.0% | 26.0% | 25.0% | 23.0% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 16 | 11 | 25 | 29 |
| Interest | 6 | 5 | 7 | 20 | 20 | 23 | 23 | 11 | 12 | 19 | 13 |
| Depreciation | 7 | 6 | 8 | 21 | 21 | 28 | 28 | 29 | 57 | 88 | 101 |
| Profit before tax | 5 | 8 | 5 | -2 | 28 | 63 | 88 | 157 | 172 | 224 | 225 |
| Tax % | 41.0% | 23.0% | 21.0% | -18.0% | 30.0% | 30.0% | 25.0% | 27.0% | 24.0% | 24.0% | — |
| Net Profit + | 3 | 6 | 4 | -2 | 20 | 44 | 66 | 114 | 131 | 170 | 174 |
| EPS in Rs | 2 | 4 | 2 | -1 | 11 | 7 | 10 | 13 | 14 | 18 | 19 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 29 | 41 | 39 | 38 | 56 | 51 | 117 | 788 | 1,509 | 1,684 |
| Borrowings + | 85 | 125 | 175 | 194 | 193 | 264 | 267 | 85 | 12 | 264 |
| Other Liabilities + | 10 | 11 | 26 | 39 | 43 | 45 | 36 | 60 | 114 | 218 |
| Total Liabilities | 138 | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 | 2,262 |
| Fixed Assets + | 54 | 53 | 164 | 189 | 251 | 303 | 299 | 442 | 605 | 1,250 |
| CWIP | 64 | 110 | 65 | 62 | 0 | 0 | 0 | 0 | 222 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74 | 2 |
| Other Assets + | 20 | 30 | 27 | 36 | 58 | 123 | 187 | 577 | 829 | 909 |
| Total Assets | 138 | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 | 2,262 |
| Equity Capital | 14 | 16 | 16 | 16 | 16 | 66 | 66 | 86 | 96 | 96 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 25 | 17 | 17 | 39 | 44 | 60 | 64 | -3 | 131 | 205 |
| Cash from Investing Activity + | -50 | -51 | -78 | -43 | -21 | -52 | -20 | -226 | -388 | -598 |
| Cash from Financing Activity + | 26 | 43 | 47 | 5 | -19 | -1 | -18 | 304 | 509 | 254 |
| Net Cash Flow | 1 | 9 | -13 | 1 | 3 | 7 | 26 | 75 | 253 | -140 |
| CFO/OP | 148 | 103 | 99 | 109 | 67 | 65 | 75 | 22 | 68 | 94 |
| Free Cash Flow | 24 | 16 | -60 | -4 | 24 | 21 | 44 | -96 | -171 | -112 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 19.37% | 22.15% | 20.15% | 19.16% | 20.2% | 17.27% | 20.35% | 20.5% | 23.16% | 27.01% | 26.94% | 27.74% |
| Promoters | 66.33% | 66.44% | 66.54% | 66.54% | 66.54% | 61.44% | 61.64% | 61.64% | 61.64% | 55.8% | 55.8% | 55.8% |
| FII | 5.42% | 2.59% | 3.99% | 4.9% | 6.28% | 9.78% | 4.45% | 4.34% | 6.51% | 6.18% | 5.25% | 5.62% |
| DII | 8.88% | 8.81% | 9.3% | 9.4% | 6.97% | 11.5% | 13.56% | 13.52% | 8.71% | 11.02% | 12.0% | 10.84% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Yatharth Hosp & Tra C S L (this stock) | 10,805 | 59.6 | 6.06 | 10.2% |
| Viyash Scientific Limited | 10,791 | 48.7 | 3.66 | 7.39% |
| Strides Pharma Sci Ltd | 10,922 | 18.8 | 3.52 | 20.0% |
| Blue Jet Healthcare Ltd | 11,040 | 78.3 | — | 52.1% |
| Healthcare Glob. Ent. Ltd | 10,558 | 219.0 | 7.93 | 2.54% |
| Metropolis Healthcare Ltd | 12,086 | 58.1 | 7.99 | 13.6% |
| Suven Life Sciences Ltd | 9,466 | — | 14.96 | -81.5% |
Which Mutual Funds Hold Yatharth Hosp & Tra C S L?
Frequently Asked Questions about Yatharth Hosp & Tra C S L
Yatharth Hosp & Tra C S L (YATHARTH) closed at ₹1,121.4 on NSE on 25 September 2026, down 35.6 (3.08%) from the previous close.
Yatharth Hosp & Tra C S L trades on the NSE (National Stock Exchange of India) under the symbol YATHARTH.
Yatharth Hosp & Tra C S L has a trailing twelve-month P/E (price-to-earnings) ratio of 59.6.
Yatharth Hosp & Tra C S L has a dividend yield of 0.04%.
Yatharth Hosp & Tra C S L's 52-week high is ₹1,184.0 and its 52-week low is ₹538.0.
Yatharth Hosp & Tra C S L has a market capitalisation of ₹10,805 crore.
Yatharth Hosp & Tra C S L has a TopFund Quality Score of 68/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Yatharth Hosp & Tra C S L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.